Synageva BioPharma Corp. PT Raised to $105.00 (GEVA)
Equities researchers at Canaccord Genuity hoisted their price target on shares of Synageva BioPharma Corp. (NASDAQ:GEVA) from $72.00 to $105.00 in a research report issued on Thursday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 18.56% from the stock’s previous close.
GEVA has been the subject of a number of other recent research reports. Analysts at Nomura initiated coverage on shares of Synageva BioPharma Corp. in a research note to investors on Wednesday, January 8th. They set a “buy” rating and a $85.00 price target on the stock. Separately, analysts at Robert W. Baird initiated coverage on shares of Synageva BioPharma Corp. in a research note to investors on Tuesday, January 7th. They set an “outperform” rating and a $83.00 price target on the stock. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Synageva BioPharma Corp. in a research note to investors on Thursday, November 14th. They set a “buy” rating and a $72.00 price target on the stock. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Synageva BioPharma Corp. has an average rating of “Buy” and an average target price of $72.63.
Shares of Synageva BioPharma Corp. (NASDAQ:GEVA) traded up 0.84% on Thursday, hitting $89.30. The stock had a trading volume of 96,942 shares. Synageva BioPharma Corp. has a 52 week low of $38.58 and a 52 week high of $88.67. The stock’s 50-day moving average is $67.36 and its 200-day moving average is $55.80. The company’s market cap is $2.745 billion.
Synageva BioPharma Corp. (NASDAQ:GEVA) last released its earnings data on Tuesday, October 29th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.13. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.81 million. Analysts expect that Synageva BioPharma Corp. will post $-3.42 EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.